Facchinetti F, Fioroni L, Sances G, Romano G, Nappi G, Genazzani A R
Department of Obstetrics and Gynecology, University of Modena, Italy.
Gynecol Obstet Invest. 1989;28(4):205-8. doi: 10.1159/000293579.
The prostaglandin system is thought to play a role in the etiology of the premenstrual syndrome. Many authors describe that prostaglandins are involved in both central and peripheral symptoms. To test this hypothesis, we studied the effects of naproxen sodium treatment (550 mg twice daily, from day -7, in relation to next menses, to the 4th day of the cycle) in 34 patients suffering from premenstrual syndrome. Six cases dropped out. Fourteen women were given placebo for the first three cycles of the trial, followed by active drug. The other 14 patients were given naproxen sodium, beginning from the first cycle. In order to evaluate premenstrual symptoms, the Moos menstrual distress questionnaire was prospectively applied during the 2-month run-in period and at the 3rd and 6th cycles of treatment. During our double-blind naproxen sodium study, both menstrual and premenstrual 'pain' decreased during active drug treatment, while placebo was ineffective. We also obtained a significant improvement of premenstrual 'behavioral changes' which is probably related to the relief of painful symptomatology. In conclusion, this study indicates that naproxen sodium is a useful and safe drug in the treatment of premenstrual and menstrual pain related symptoms.
前列腺素系统被认为在经前综合征的病因学中起作用。许多作者描述前列腺素与中枢和外周症状均有关。为了验证这一假设，我们研究了萘普生钠治疗（550毫克，每日两次，从与下次月经相关的第 -7天至周期的第4天）对34例经前综合征患者的影响。6例退出。14名女性在试验的前三个周期服用安慰剂，随后服用活性药物。另外14名患者从第一个周期开始服用萘普生钠。为了评估经前症状，在2个月的导入期以及治疗的第3和第6周期前瞻性地应用了莫斯月经困扰问卷。在我们的双盲萘普生钠研究中，在活性药物治疗期间，月经和经前“疼痛”均减轻，而安慰剂无效。我们还在经前“行为改变”方面取得了显著改善，这可能与疼痛症状的缓解有关。总之，本研究表明萘普生钠是治疗经前和月经疼痛相关症状的一种有用且安全的药物。
